Patricia Van Arnum

Editorial Director, DCAT

patricia@dcat.org
Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members. She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees. Overall, she has more than 25 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.

LATEST

Drug Products: Key Trends & Recent Approvals
By

By
What are noteworthy trends in drug delivery and drug-product development in key dosage forms: solid dosage and parenteral drugs? A look at key technology advances and recent new drug approvals.

US Drug Pricing Reforms Move Forward
By

By
Rx drug pricing reform in the US took a major step this week with the passage of a Senate bill, which now goes to the House of Representatives, where it is likely to pass. What is in the plan?

FDA & Remote Inspections: What Is Next?
By

By
The FDA has issued draft guidance to lay out its current thinking on remote regulatory assessments, an approach it took when onsite inspections were not possible due to the COVID-19 pandemic. What’s in the plan?

Emerging Pharma: Top Moves Thus Far in 2022
By

By
Emerging Pharma companies are important as drug-development partners with larger bio/pharma companies and represent an important customer base for CDMOs/CMOs. Which companies and their deals have stood out this far in 2022?

Mid-Year Review: New Drug Approvals Thus Far in 2022
By

By
As we move past the mid-way mark in 2022, how has the industry fared with new drug approvals? Is the industry keeping pace with prior years’ innovation levels? What do the  numbers show, including the mix between small molecules and biologics?

EU’s Gas Demand-Reduction Plan: Impact on Pharma
By

By
The European Union agreed this week to reduce natural gas demand by 15%, starting August 1 and lasting through next March, to prepare for possible disruptions of gas supplies from Russia. The EU chemical and pharma industries weigh in.

What’s Next for the New GSK After Consumer Healthcare Spin-off?
By

By
GlaxoSmithKline has completed the spin-off of its consumer healthcare business to form a separate stand-alone $11-billion company, Haleon. The move is part of a larger strategic plan by GSK’s CEO Emma Walmsley to drive growth in its core bio/pharmaceuticals business. What is next for the New GSK?

Supplier Relationship Management: Examining the Talent of the Future
By

By
How are the skillsets for sourcing, procurement, and supply management professionals evolving to meet future talent needs, including digital capabilities? What will be needed for effective supplier relationship management in the future both from pharma companies and suppliers?

Big Pharma’s Manufacturing Investments
By

By
What have been some key recent investments in manufacturing by the large bio/pharmaceutical companies? What areas, small-molecule APIs, biologics, or drug products, have been attracting the investment dollars? DCAT Value Chain Insights rounds up key projects.

Evaluating FDA’s Foreign Mfg Inspections
By

By
A recent US government report evaluated the FDA’s process for for-cause inspections of foreign drug-manufacturing facilities. Although the FDA has made changes to improve the process, Congress and others have raised concerns. What did the review show?